News
Health~Holland Update November 2017
In this winter Update, we commemorate Jan Raaijmakers, former chairman of the Top Sector LSH, who passed away and whose spirit we will cherish. We shed some light on the recent news that EMA will move to the Netherlands and announce our new Immunology Call. In the agenda section we inform you on upcoming events like the BIO Europe Spring, Innovation for Health and more major meetings.
Cristal Therapeutics Awarded €2.5 Million Horizon 2020 Grant to Advance Its CriPec-docetaxel through Phase 2 trials
Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announced that it secured a €2.5 million grant from the European Commission’s Horizon 2020 programme. The funds will be used to perform the upcoming Phase 2 trials of Cristal Therapeutics’ lead nanomedicine candidate CriPec-docetaxel.
The ‘Course ‘Partner in Balance’ by dementia’ wins the Medical Inspirator award 2017!
After an intense period in which a lot of campaign is conducted for the Medical Inspirator award and the three nominated research projects, the winner is announced this 23rd November at the VSNU Impact festival. First place goes to ‘Course ‘Partner in Balance’ by dementia’. This project receives €75.000 to spend on their research. With this prize the researcher Lizzy Boots (MUMC) and patient representative Mrs. Jennie Tillie-Hecker wants to further develop their course, which helps caretakers to deal with the insecurities and questions after the diagnose dementia.
Cyclomics: Winner of the Venture Challenge Fall 2017
Today at the Dutch Life Sciences Conference 2017, Chrétien Herben, director of the LifeSciences@Work Accelerator, announced Cyclomics as winning team of the 18th edition of the Venture Challenge. The start-up Cyclomics has developed a technology to measure cancer recurrence in liquid biopsies, by detection of cancer mutations in blood at single-molecule sensitivity. This way the start-up aims to improve survival for many different types of cancer.
EMA to relocate to Amsterdam, the Netherlands
The European Medicines Agency (EMA) will relocate to Amsterdam in the Netherlands. The agency is responsible for the approval of medicines on the European market. EMA has to relocate due to the United Kingdom’s decision to withdraw from the EU. The Agency now has just over 16 months to prepare for the move and take up its operations in Amsterdam on 30 March 2019 at the latest.
AJCC Confirms MammaPrint’s Clinical Utility for Treatment Decisions and Staging in Recent 8th Edition Breast Chapter Update
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the American Joint Committee on Cancer (AJCC) has recently issued a Breast Cancer Update and Correction which revised and clarified the Cancer Staging Manual, 8th Edition regarding the use of multigene genomic profiles for Pathological Prognostic Staging.
Animal-friendly and effective medicine test Mimetas receives second innovation credit
Het Leidse bedrijf Mimetas ontvangt tijdens het bezoek van staatssecretaris Keijzer van Economische Zaken en Klimaat (EZK) een tweede Innovatiekrediet ter waarde van € 2 miljoen. Mimetas benut deze steun voor de doorontwikkeling van personalized medicine: bijvoorbeeld een tool om de oncoloog te helpen bij de behandelkeuze van verschillende kankers.
Building on Cures Act, FDA lays out cell therapy fast track in regenerative medicine framework
The FDA has created a policy framework for cellular therapies and other regenerative medicines by releasing two draft and two final guidance documents. Publication of the texts builds on the 21st Century Cures Act by setting criteria for the new Regenerative Medicine Advanced Therapy (RMAT) designation and outlining the benefits of the regulatory status.
hDMT seeks collaborators for €4M NWO-TTW Perspectief Program proposal
hDMT is the Dutch Organ-on-Chip consortium, with currently near 100 affiliated research leaders. hDMT’s researchers work in fourteen academic research institutions, university medical centers and biotechnology companies. They share their knowledge and expertise to develop Organ-on-Chip models, by integrating state-of-the-art human stem cell technologies and top level engineering with a wide variety of other disciplines.
Xeltis Closes €45 Million Series C Financing
Xeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed €45 million ($52 million) Series C financing.